ArticleKorean journal of anesthesiology2021
Obesity and anesthetic pharmacology: simulation of target-controlled infusion models of propofol and remifentanil.
Article in Korean journal of anesthesiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Target-Controlled Infusion of Propofol: A Systematic Review of Recent Results.Journal of medical systems · 2025Pooled it
- Obesity Reduces the Median Effective Dose of Remimazolam in Aged 6-18 Pediatric Patients for Procedural Sedation.Drug design, development and therapy · 2026Trial
- Efficacy and safety of ciprofol for gastroscopy in patients with obesity: a randomised clinical controlled trial using different weight-based dosing scales.BMC anesthesiology · 2025Trial
- Impact of Body Weight on Sedation-Related Outcomes in Complex Electrophysiological Interventions.Healthcare (Basel, Switzerland) · 2026Article
- Comparison of intraoperative hemodynamic parameters between propofol- and remimazolam-based total intravenous anesthesia in patients undergoing robotic gynecologic surgery: a randomized controlled trial protocol.Frontiers in pharmacology · 2026Article
- Weight-Scaled Dose Optimization of Intravenous Anesthetics in Patients with Obesity: General Anesthesia and Procedural Sedation.Drug design, development and therapy · 2026Review
- Determination of the 95% Effective Dose of Remifentanil for Moderate Sedation During Gastroscopy in Obese Patients.Current medicinal chemistry · 2026Article
- Determination of ED50 and ED95 for Ciprofol in Morbidly Obese Patients During Induction of General Anesthesia: A Single-Center, Up-and-Down Study Based on Lean Body Weight.Drug design, development and therapy · 2026Article
- Modeling drug retention as memory effects in obese patients using fractional and augmented models.Scientific reports · 2025Article
- Risk factors for adverse reactions to nurse-administered propofol during outpatient endoscopy: a cross-sectional study.BMC anesthesiology · 2025Article
- Propofol-alone sedative efficacy in observational biliopancreatic endoscopic ultrasound.DEN open · 2025Article
- Efficacy and Safety of Ciprofol for Anesthesia in Painless Colonoscopy with Varying Body Mass Indices Patients: A Prospective, Single-Center, Observational Study.Drug design, development and therapy · 2025Observational
- Advances in Canine Anesthesia: Physiologically Based Pharmacokinetic Modeling for Predicting Propofol Plasma Profiles in Canines with Hepatic Impairment.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Patients' perioperative experiences of an opioid-free versus opioid-based care pathway for laparoscopic bariatric surgery: A qualitative study.International journal of nursing studies advances · 2024Article
- Article
- Review
- Comparison of Fat-Free Mass and Ideal Body Weight Scalar for Anesthetic Induction Dose of Propofol in Patients with Morbid Obesity: A Double-Blind, Randomized Clinical Trial.Anesthesiology and pain medicine · 2023Article
- Effects of body mass index on propofol-induced cardiovascular depression in the Pakistani population.Pakistan journal of medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of obesity is increasing, resulting in an increase in the number of surgeries performed to treat obesity and diseases induced by obesity. The associated comorbidities as well as the pharmacokinetic and pharmacodynamic changes that occur in obese patients make it difficult to control the appropriate dose of anesthetic agents. Factors that affect pharmacokinetic changes include the increase in adipose tissue, lean body weight, extracellular fluid, and cardiac output associated with obesity. These physiological and body compositional changes cause changes in the pharmacokinetic and pharmacodynamic parameters. The increased central volume of distribution and alterations in the clearance of drugs affect the plasma concentration of propofol and remifentanil in the obese population. Additionally, obesity can affect pharmacodynamic properties, such as the 50% of maximal effective concentration and the effect-site equilibration rate constant (ke0). Conducting a simulation of target-controlled infusions based on pharmacokinetic and pharmacodynamic models that include patients that are obese can help clinicians better understand the pharmacokinetic and pharmacodynamic changes of anesthetic drugs associated with this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.